B. Riley Comments on Lineage Cell Therapeutics Q1 Earnings

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) – Investment analysts at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for Lineage Cell Therapeutics in a research note issued to investors on Thursday, March 13th. B. Riley analyst M. Mamtani forecasts that the company will post earnings per share of ($0.03) for the quarter. B. Riley currently has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.12) per share. B. Riley also issued estimates for Lineage Cell Therapeutics’ Q2 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.03) EPS and FY2027 earnings at ($0.08) EPS.

A number of other analysts have also weighed in on the company. Maxim Group lowered their target price on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, January 10th. D. Boral Capital restated a “buy” rating and issued a $2.00 target price on shares of Lineage Cell Therapeutics in a research note on Tuesday, March 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Lineage Cell Therapeutics in a research report on Tuesday, March 11th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $4.20.

Lineage Cell Therapeutics Stock Performance

Shares of NYSEAMERICAN LCTX opened at $0.48 on Monday. Lineage Cell Therapeutics has a 52-week low of $0.48 and a 52-week high of $1.61. The company has a market capitalization of $106.18 million, a PE ratio of -4.01 and a beta of 1.21. The firm’s fifty day moving average is $0.60.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Institutional investors have recently modified their holdings of the stock. Fort Sheridan Advisors LLC grew its position in shares of Lineage Cell Therapeutics by 71.5% during the 4th quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company’s stock worth $28,000 after buying an additional 23,000 shares during the period. Atria Wealth Solutions Inc. bought a new position in shares of Lineage Cell Therapeutics during the 4th quarter valued at about $29,000. HighTower Advisors LLC lifted its holdings in shares of Lineage Cell Therapeutics by 49.5% during the 4th quarter. HighTower Advisors LLC now owns 57,706 shares of the company’s stock valued at $29,000 after purchasing an additional 19,100 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of Lineage Cell Therapeutics by 35.5% during the 4th quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock valued at $35,000 after purchasing an additional 18,053 shares in the last quarter. Finally, Two Sigma Advisers LP lifted its stake in Lineage Cell Therapeutics by 312.2% in the 4th quarter. Two Sigma Advisers LP now owns 86,964 shares of the company’s stock valued at $44,000 after acquiring an additional 65,864 shares in the last quarter. 62.47% of the stock is currently owned by institutional investors and hedge funds.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.